This week on WealthTrack, Consuelo Mack calls into question the long-dominant efficient market theory and explores what models should be used by investors to navigate the markets. She discusses this with two top fund managers, Jerry Senser, a former Morningstar Fund Manager of the Year and the lead portfolio manager for all of ICAP, including their MainStay ICAP Funds, and noted contrarian Robert Kleinschmidt, who manages the top-rated Tocqueville Fund. Also joining the conversation is Justin Fox, Time magazine’s economics columnist and author of “The Myth of the Rational Market”. As always with WealthTrack this is excellent viewing material.

Note: The transcript of this interview is not available yet, but will be posted here as soon as it arrives.

Source: Wealthtrack, October 16, 2009.

Did you enjoy this post? If so, click here to

This week in WealthTrack’s series on Great Investors, Consuelo Mack features two legendary value investors whose long-term records are among the best in the business. Interestingly, they have taken very different approaches to the markets since last year’s financial crisis.

“The first is Jean-Marie Eveillard, until recently the long-time lead portfolio manager of the First Eagle funds for which he received Morningstar’s lifetime achievement award for one of the most successful long-term records in the investment business. Jean-Marie is known for his defensive value style of investing. He believes it remains the best strategy to follow.

“The other is his close friend, Marty Whitman. Marty is the celebrated portfolio manager of the Third Avenue funds and one of the deans of value investing.  He is also the author of several books. His most recent, Distress Investing is a primer on one of his areas of expertise. He also wrote

Today we are featuring top-performing “Health" equity mutual funds, which primarily invest in equity securities of companies from the health care sector or related industries.

Investors can find such funds by checking out the entire list of the Zacks #1 Rank Heath Equity Funds.

3 Strong Samples

Rydex Biotechnology Inv (RYOIX) seeks capital appreciation by investing in equity securities of biotechnology companies that are traded in the United States.

The fund may also engage in futures and options transactions, purchase ADRs and U.S. government securities, and enter into repurchase agreements. It is non-diversified.

Amgen Inc. (AMGN), Gilead Sciences Inc. (GILD) and Celgene Corp. (CELG) are among the fund’s key holdings.

Putnam Global Health Care A (PHSTX) was founded in May 1982 and seeks capital appreciation.

Although the fund can invest in companies of any size, it primarily invests in large and

Today we are featuring top-performing "Pacific" equity mutual funds, which primarily invest in stocks of companies that are based in.

Investors can find such funds by checking out the entire list of the Zacks #1 Rank Pacific Equity Funds.3 Pacific Picks

SPARX Asia Pacific Equity Income (SPAIX) was incepted in August 2007 and seeks long-term capital appreciation. The fund is non-diversified.

The fund normally invests at least 80% of its net assets in dividend-paying companies located in the Asia Pacific region, excluding Japan. It invests in companies regardless of market capitalization.

Tom Naughton has been the lead portfolio manager at the fund since its inception, focusing exclusively on Asia ex-Japan. The fund has an expense ratio of 1.60%.

Fidelity Advisor Emerging Asia A (FEAAX) seeks long-term capital appreciation. It normally invests primarily in common stocks of Asian emerging market